Sometimes big breakthroughs in science come from very small changes, curiosity, and more than a little luck. A new study from ...

With immunology and inflammation blockbusters like AbbVie’s Skyrizi and Rinvoq reeling in nearly $7 billion combined in the ...

One of the FDA’s potential approvals this month could break an existing monopoly in the treatment space for a rare growth ...

Nektar Therapeutics develops novel immunomodulatory drugs targeting autoimmune diseases and oncology. Click here to read why ...

Focusing on pharmacokinetic and pharmacodynamic mechanisms, Dr Erin C Berthold discusses the interactions between botanical ...

Phase 2a data support oral C5aR inhibitor INF904 as a potentially transformational and best-in-class immunomodulatory agent, indicating strong ...

AI can help humans reach their cognitive “flow state,” says author Mithu Storoni, by balancing challenge and ability.

And good afternoon, and welcome everyone to the Relmada Therapeutics, Inc. Third Quarter 2025 Conference Call. 2025 is ...

Relmada Therapeutics, Inc. misses on earnings expectations. Reported EPS is $-0.30404 EPS, expectations were $-0.04. Operator ...

Eli Lilly and Company (NYSE: LLY) today announced positive results from a Phase 2 trial evaluating the safety and efficacy of ...